Cyteir Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Cyteir Therapeutics, Inc. (Nasdaq: CYT) announced that its President and CEO, Markus Renschler, MD, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 2:15 PM ET. The virtual event allows investors to access a live webcast on the Cyteir website, with a replay available for 30 days after the presentation. Cyteir is a clinical-stage oncology company focused on developing next-generation synthetically lethal therapies for cancer, including its lead compound, CYT-0851, aimed at inhibiting RAD51-mediated homologous recombination.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD, will present at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually on Wednesday, January 12, 2022, at 2:15pm ET.

A live webcast of the presentation will be available in the Investors & Media section of the Cyteir website at www.cyteir.com. A webcast replay will also be available on the website shortly after conclusion of the event for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005085/en/

INVESTOR:

Lisa Hayes

Vice President, Investor Relations and Corporate Communications

908-868-8926

Lisa.Hayes@cyteir.com

MEDIA:

Michele Parisi

925-429-1850

mparisi@forwardhealthinc.com

Source: Cyteir Therapeutics

FAQ

When will Cyteir Therapeutics present at the J.P. Morgan Healthcare Conference?

Cyteir Therapeutics will present at the J.P. Morgan Healthcare Conference on January 12, 2022, at 2:15 PM ET.

Where can I watch the Cyteir Therapeutics presentation?

The Cyteir Therapeutics presentation can be watched live on their website in the Investors & Media section.

What is CYT-0851?

CYT-0851 is Cyteir Therapeutics' lead compound, designed to inhibit RAD51-mediated homologous recombination and repair of double-strand DNA breaks.

How long will the Cyteir Therapeutics presentation be available for replay?

The replay of the Cyteir Therapeutics presentation will be available on their website for 30 days after the event.